Adakveo האיחוד האירופי - רומנית - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Oxbryta האיחוד האירופי - רומנית - EMA (European Medicines Agency)

oxbryta

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Zydelig האיחוד האירופי - רומנית - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisibul - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Teysuno האיחוד האירופי - רומנית - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - neoplasme de stomac - agenți antineoplazici - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

FOSTER NEXTHALER 200 micrograme/6 micrograme רומניה - רומנית - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

foster nexthaler 200 micrograme/6 micrograme

chiesi farmaceutici s.p.a. - italia - combinatii (beclometasonum+formoterolum) - pulb. de inhal. - 200micrograme/6micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r

Memantine Mylan האיחוד האירופי - רומנית - EMA (European Medicines Agency)

memantine mylan

mylan pharmaceuticals limited - memantină clorhidrat - boala alzheimer - other anti-dementia drugs, psychoanaleptics, - tratamentul pacienților cu boală alzheimer moderată până la severă.

Takhzyro האיחוד האירופי - רומנית - EMA (European Medicines Agency)

takhzyro

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedem, ereditar - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Luxturna האיחוד האירופי - רומנית - EMA (European Medicines Agency)

luxturna

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna este indicat pentru tratamentul pacienților adulți și pacienți copii și adolescenți cu pierderea vederii din cauza moștenit distrofie retinei cauzate de confirmat biallelic rpe65 mutații și care au suficient de viabile celulele retinei.

Zynteglo האיחוד האירופי - רומנית - EMA (European Medicines Agency)

zynteglo

bluebird bio (netherlands) b.v. - autolog de celule cd34+ celule îmbogățit populației, care conține celule stem hematopoietice transduced cu lentiglobin bb305 lentivirali vectorul de codare beta-o-t87q-gena globinei - beta-talasemie - other hematological agents - zynteglo este indicat pentru tratamentul pacienților 12 ani și mai în vârstă cu dependentă de transfuzie β talasemie (tdt) care nu au un β0/β0 genotip, pentru care de celule stem hematopoietice (hsc) transplantul de organe este cazul, dar un antigenul leucocitar uman (hla)-potrivire legate hsc donator nu este disponibil.